This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Why Are We Still Waiting for Biosimilars?
By applying “common sense,” President Trump has an opportunity to help get the industry moving and make a real mark on US healthcare by boosting biogeneric use.
